TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04875806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC762
Description: NC762 is an experimental antibody drug that may make the immune response more active against cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC762
Description: NC762 is an experimental antibody drug that may make the immune response more active against cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC762
Description: NC762 is an experimental antibody drug that may make the immune response more active against cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC762
Description: NC762 is an experimental antibody drug that may make the immune response more active against cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NC762
Description: NC762 is an experimental antibody drug that may make the immune response more active against cancer
Study: NCT06053658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given by IV (vein)
Study: NCT06470373

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eylea® Solution for intravitreal injection
Description: Administer 2 mg/eye (50 uL/eye) per dose of the IP via IVT to the subjects' study eye
Study: NCT04590547

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLS-1027
Description: GLS-1027 is an oral medication with high bioavailability that has IL-6 and IL-1β inhibitory activity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLS-1027
Description: GLS-1027 is an oral medication with high bioavailability that has IL-6 and IL-1β inhibitory activity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo looks like GLS-1027
Study: NCT05224947

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant Formula
Description: Two infant formulas differing in composition

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant Formula
Description: Two infant formulas differing in composition
Study: NCT06406205

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voclosporin（QL1074）
Description: QL1074 23.7 mg BlD will be administered as a fixed dose without the use of therapeutic drugmonitoring. The protocol contains provisions for management of dose based on safety concerns, in particular, BP and renal function，can be managed by dose reduction and temporary of QL1074 to interruption.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo softgel capsules, identical to 7.9 mg QL1074, will be provided. The administration plan and dosage management regulations are the same as QL1074.
Study: NCT04801446

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Soterix Medical 1X1 tDCS stimulator (active C-tDCS)
Description: Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. There will be 6 dose tiers, reflecting increasing intensity and duration of stimulation: Tier 1 - 1 mA, single 20 - min cycle; Tier 2- 2 mA, single 20 min cycle; Tier 3 - 1 mA, 2 cycles of 20 min/20 min off; Tier 4- 2 mA, 2 cycles of 20 min/20 min off; Tier 5 - 1 mA, 3 cycles of 20 min/20 min off; Tier 6 - 2 mA, 3 cycles of 20 min/20 min off.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Soterix Medical 1X1 tDCS stimulator (sham stimulation)
Description: Patients will be randomized to active treatment (C-tDCS) vs sham stimulation in a 3:1 ratio. Patients in the sham stimulation arm at all the tiers will have the headgear and electrodes in place, and the switch for sham stimulation will be on, i.e. no prolonged electrical stimulation will be delivered.
Study: NCT06430372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bev-ICG
Description: Probe targeting VEGF-A that is topically administrated during the endoscopy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIR-II fluorescence endoscopy platform
Description: An endoscopic detection device which can detect and visualize NIR-II fluorescent signal during the endoscopy
Study: NCT05474144

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SmartProbio C
Description: Probiotic supplement consisting of 19 strains (Lactobacillus acidophilus NCFM, Bifidobacterium lactis, subsp. Infantis Bi-07, Lactobacillus rhamnosus LR22, Lactobacillus acidophilus LA14, Lactobacillus rhamnosus LGG, Bifidobacterium lactis HN019, Bifidobacterium lactis Bl-04, Lactobacillus acidophilus LA 11 ONLLY, Lactobacillus rhamnosus HN001, Lactobacillus plantarum LP ONLLY, Lactobacillus casei LC18, Bifidobacterium breve BB8, Lactobacillus reuteri LE16, Bifidobacterium lactis BI516, Streptococcus thermophilus ST6, Bifidobacterium animalis BA77, Bifidobacterium bifidum BB47, Bifidobacterium longum BL88 ONLLY, Bifidobacterium infantis BI211) in different ratios. Probiotic mixture enclosed in HPMC (hydroxypropylmethylcelulose) capsule, 25 billion CFU (colony-forming units) in each capsule. As a filling agent mix of inulin and maltodextrin was used. Dosage twice a day.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo. HPMC (hydroxypropylmethylcelulose) capsule filled with maltodextrin. Dosage twice a day.
Study: NCT05457881

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Scandi-Shake
Description: Scandi-Shake \[any of 4 flavors - vanilla, strawberry, banana cream, and caramel\] mixed with almond milk (85 grams Scandi-Shake mix to 240 cc almond milk), calculated individually for a total daily volume to achieve 30% caloric restriction and 70% protein restriction, based on ideal body weight. The Mifflin St. Jeor equation will be used to calculate the total 24-hour energy needs based on gender, age, height, weight, and activity factor for the PCR diet. Daily physical activity will be assessed by questionnaire to determine the activity factor for accurate calorie restriction calculations. Nutritionists will use this equation to create a unique shake for each individual patient. The shakes will be separated into 4 equal portions per day, for a total of 16 portions across the 4 pre-operative days. Patients can consume the 4 daily portions at whichever time of day they choose. The shakes are frozen 24 hours before distribution.
Study: NCT05486949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4205 and carbamazepine
Description: All subjects will receive AZD4205 single dose on Day 1, and the second dose of AZD4205 along with carbamazepine after the wash-out period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4205 and itraconazole
Description: All subjects will receive AZD4205 single dose on Day 1, and the second dose of AZD4205 along with itraconazole after the wash-out period.
Study: NCT05942456

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA: enzyme-linked immunosorbent assay
Description: enzyme-linked immunosorbent assay

Intervention type: DIAGNOSTIC_TEST
Intervention: ELISA: enzyme-linked immunosorbent assay
Description: enzyme-linked immunosorbent assay
Study: NCT05566730

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CT-MICART App
Description: App designed with the goal of treating CUD in African American adults

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: App designed with the goal of treating CUD in African American adults, with participants just tracking their use of cannabis and not receiving treatment videos
Study: NCT05046782

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: restriction spectrum imaging (RSI)
Description: detect prostate cancer better than a standard-of-care MRI
Study: NCT06167096

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lavender essential oil
Description: Lavender Oil; blend of two (2) pure lavender oil - Lavandula angustifolia from Bulgaria and Lavandula hybrida from France

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Water
Description: Water
Study: NCT06456021

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Relational Playbook
Description: The Relational Playbook consists of 5 chapters and hosts research-based resources and 50 evidence-based interventions presented in short, digestible content to create supportive learning environments. Implementation is guided by 4-steps: Step 1) Assess the current state: CCL managers assesses the current state of their learning environment through a 13-item Learning Environment Assessment Tool. Results are automatically scored and grouped by Playbook chapters. A summary report is immediately available with guidance on how to interpret results. Step 2) Select areas for improvement: CCL managers determine which Playbook chapters and interventions to adopt. Step 3) Implement/adapt interventions: Over the 6-month intervention period, CCL managers are required to implement interventions from 2-3 Playbook chapters. They may adapt the delivery method/implement additional interventions. Step 4) Evaluate the impact: CCL managers develop feedback loops to monitor intervention performance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: The Relational Playbook
Description: The Relational Playbook consists of 5 chapters and hosts research-based resources and 50 evidence-based interventions presented in short, digestible content to create supportive learning environments. Implementation is guided by 4-steps: Step 1) Assess the current state: CCL managers assesses the current state of their learning environment through a 13-item Learning Environment Assessment Tool. Results are automatically scored and grouped by Playbook chapters. A summary report is immediately available with guidance on how to interpret results. Step 2) Select areas for improvement: CCL managers determine which Playbook chapters and interventions to adopt. Step 3) Implement/adapt interventions: Over the 6-month intervention period, CCL managers are required to implement interventions from 2-3 Playbook chapters. They may adapt the delivery method/implement additional interventions. Step 4) Evaluate the impact: CCL managers develop feedback loops to monitor intervention performance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leadership Coaching
Description: Leadership coaching is a novel implementation strategy that enables proactive, knowledgeable, and supportive leadership behaviors. Although coaching has been embraced in the VA, through Whole Health and the VA Leadership Coaching Program, no studies have examined the impact on innovation implementation with clinical managers.
Study: NCT05552391

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: Group bupivacaine(Control) (B) received 0.5 ml/kg bupivacaine 0.25% diluted with isotonic saline (total volume15 ml).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Group bupivacaine(Control) (B) received 0.5 ml/kg bupivacaine 0.25% diluted with isotonic saline (total volume15 ml).
Study: NCT05283096

Intervention type: OTHER
Intervention: Questionnaire
Description: A questionnaire about beliefs on food and diet in rheumatic diseases, and if a diet was tried what effect it had on health and rheumatism
Study: NCT04524962

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Descartes 30
Description: Mesenchymal Stem Cells or MSCs RNA-engineered to secrete a combination of DNases.
Study: NCT06040346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meplazumab for Injection
Description: Meplazumab, an erythrocytic stage-macromolecular antibody drug, has the potential to control clinical occurrence of falciparum malaria. Meplazumab is a humanized anti-CD147 immunoglobulin G subclass 2 (IgG2) monoclonal antibody with strong affinity to CD147. CD147 is expressed on erythrocyte lineage cells throughout erythroid development, including mature erythrocytes and is the target for Plasmodium merozoites to allow reorientation and subsequent invasion of the erythrocytes.
Study: NCT04387162

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prism Adaptation Treatment
Description: Spatial retraining treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prism Adaptation Treatment
Description: Spatial retraining treatment
Study: NCT05906017

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open Hernia surgery
Description: midline ventral hernia repair - open

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic Hernia surgery
Description: midline ventral hernia repair - robotic
Study: NCT05004922

Intervention type: OTHER
Intervention: Embryo transfer into upper cavity
Description: Transfer of embryos in upper cavity

Intervention type: OTHER
Intervention: Embryo transfer into midcavity
Description: Transfer of embryos in mid cavity
Study: NCT06289413

Intervention type: OTHER
Intervention: Development of AD/OI after BS
Description: OI is a type of AD that results in chronic supine-to-standing hypotension and disabling dizziness, lightheadedness, and even syncope. Whether arising from malabsorption, vagus nerve damage, or splanchnic vasodilation, the pathophysiology of OI in bariatric surgery is not clear and requires more investigation.~Treatment of OI usually consists of dietary and lifestyle changes, which may include compression stockings and abdominal binders. Medical options include peripheral vasoconstrictors and mineralocorticoids; some patients may be referred to Cardiology for further testing. Management is difficult and endurance and tilt training, inflatable abdominal bands, and beta-blockers have been proposed. One recent study demonstrated the treatment of refractory OI with Droxidopa. Yet, the success of treatment is individualized and necessitates more novel approaches.
Study: NCT05540392

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: 10 treatments of acupuncture over the course of 10 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Waitlist Control
Description: The waitlist control group will not receive any acupuncture treatments during the 14-week waiting period. Patients in waitlist control group will have the option to receive up to 10 acupuncture treatments after a 14-week waiting period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Patients will complete Patient Reported Outcomes (PRO)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Patients will complete Patient Reported Outcomes (PRO)
Study: NCT05597020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant
Description: Daridorexant is available as oral film-coated tablets at a strength of 50 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching daridorexant is provided as identical-looking oral tablets, formulated with the same inactive ingredients (excipients) as the active tablets.
Study: NCT04897581

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Therapy for Insomnia, BBTI
Description: BBTI includes sleep hygiene, stimulus control, and sleep restriction, and is administered in three 50-minute sessions over telehealth by psychologic team.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Self-Regulation, PSR
Description: PSR is conducted over telehealth and consists of three 50-minute sessions focused on jaw relaxation exercises, proprioceptive awareness training, and diaphragmatic breathing entrainment.
Study: NCT06347354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine green
Description: Subdermal injection of 2,5 mg (1 cc) of ICG
Study: NCT05949086

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Work Chat
Description: Work Chat will be a simulation training using virtual characters to role-play conversations. It will contain conversations with a coworker, a customer, and a supervisor within a workplace setting.
Study: NCT05007873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine and Cedazuridine
Description: Given PO
Study: NCT06534021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IASO-782 injection
Description: Each subject will be given only one dose of IASO-782. Subjects should avoid strenuous exercise within 48 h before administration and remain seated or semi-recumbent (except for necessary activities) for 4 h after administration. IASO-782 solution for injection or placebo was diluted in 0.9% sodium chloride injection (corresponding to the dose administered according to the body weight at baseline and the dose group) with a total volume of 250 mL, administered as a single intravenous drip at a drip rate recommended by the drug manual on the day of administration, The infusion time is about 90 minutes (± 15 minutes).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Each subject will be given one dose of placebo. Subjects should avoid strenuous exercise within 48 h before administration and remain seated or semi-recumbent (except for necessary activities) for 4 h after administration. IASO-782 solution for injection or placebo was diluted in 0.9% sodium chloride injection (corresponding to the dose administered according to the body weight at baseline and the dose group) with a total volume of 250 mL, administered as a single intravenous drip at a drip rate recommended by the drug manual on the day of administration, The infusion time is about 90 minutes (± 15 minutes).
Study: NCT05755373

Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given
Study: NCT05535192

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THRIVE
Description: The THRIVE Intervention will involve:~1) one in-person exercise sessions, followed by twice-weekly, home-based exercise sessions, supervised remotely through telehealth, and 2) a remotely delivered dietary assessment and recommendations to support protein intake throughout the study

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Support Program
Description: Participants will receive a tablet with information and resources regarding mediation, stretching and gentle movement, relaxation and creative arts during chemotherapy
Study: NCT05552391

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Group bupivacaine(Control) (B) received 0.5 ml/kg bupivacaine 0.25% diluted with isotonic saline (total volume15 ml).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Hydrochloride
Description: Group bupivacaine - ketamine (K) received 0.5 ml/kg bupivacaine 0.25% with ketamine 2 mg/kg, diluted with isotonic saline (total volume15 ml).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Hydrochloride
Description: Group bupivacaine - Dexametomedine (D) received 0.5 mL/kg bupivacaine 0.25% with dexmedetomidine 1 µg/kg. diluted with isotonic saline (total volume 15ml).
Study: NCT05254015

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST)
Description: Cognitive Rehabilitation and Exposure/Sorting Therapy (CREST) includes cognitive rehabilitation of executive functioning and exposure therapy for discarding/not acquiring.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Case Management
Description: Case management includes linking to resources, monitoring health, and safety hazards.
Study: NCT06663644

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Muscle energy technique on iliotibial band
Description: Post isometric relaxation involves the peripheral and central modulating mechanism by activating the muscles and joint mechanoreceptors. It can be effective for a variety of purposes including lengthening a shortened muscles, as a lymphatic or venous pump to aid the drainage of fluid or blood and increasing the range of motion. MET is a manual therapy intervention that can be used to stretch or lengthen muscles and fascia that lack flexibility.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hamstring and abdominal muscle activation
Description: The 90/90 exercises for abdominal and hamstring activation rotate the pelvis posteriorly in the sagittal and transverse plane, into a more neutral position. Hamstrings extend the hip, and therefore reciprocally inhibit hip flexors. Hamstrings and abdominals also aid in inhibiting paraspinal muscles via a posterior pelvic tilt / hip extension, a decrease in lumbar extension, and an increase in lumbar flexion.
Study: NCT06664268

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Plasma rich in growth factors (PRGF-Endoret)
Description: Plasma Rich Fibrin (PRF) is a newer modality in regenerative medicine derived from the patient's own blood. PRF does not use anticoagulants during processing, leading to a natural fibrin matrix that supports prolonged release of growth factors and cytokines .This matrix has been shown to enhance wound healing and improve scar texture and appearance .

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional CO2 laser assisted PDT
Description: Fractional CO2 laser therapy is a well-established technique for scar treatment, including postburn scars. This technology utilizes laser energy to create microthermal zones in the skin, which stimulates collagen production and skin remodeling while minimizing damage to surrounding tissues .

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional CO2 laser assisted PDT
Description: Fractional CO2 laser therapy is a well-established technique for scar treatment, including postburn scars. This technology utilizes laser energy to create microthermal zones in the skin, which stimulates collagen production and skin remodeling while minimizing damage to surrounding tissues .
Study: NCT06664346

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Immersive virtual reality mindfulness
Description: Immersive virtual reality mindfulness

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Immersive virtual reality mindfulness
Description: Immersive virtual reality mindfulness
Study: NCT06663150

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health intervention with a socio-community approach
Description: The intervention consists of five components, including education, cognitive stimulation, physical activity, nutrition, and socio-community aspects. The duration of the intervention will be 6 months and will be conducted in either in-person or virtual format, individually or in groups, depending on the nature of each component. Mode of Delivery:~The intervention will be offered in both in-person and synchronous virtual formats. Participants who are unable to attend in person or who face difficulties doing so on any occasion will have the option to join the sessions through a real-time videoconferencing platform. In both modalities, the professionals in charge will supervise and guide the activities, ensuring proper execution and adherence to the study's objectives. The research team will maintain a detailed record of attendance and participation using the RedCap platform for appropriate tracking.